{"id":27125,"date":"2024-10-01T09:40:32","date_gmt":"2024-10-01T07:40:32","guid":{"rendered":"https:\/\/ggba.swiss\/perivision-secures-chf-1-1-million-grant-for-retinal-disease-research\/"},"modified":"2024-10-01T09:43:23","modified_gmt":"2024-10-01T07:43:23","slug":"perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/","title":{"rendered":"PeriVision obtient CHF 1,1 million pour la recherche sur les maladies de la r\u00e9tine"},"content":{"rendered":"\n<p><a href=\"https:\/\/www.perivision.com\/\">PeriVision<\/a>, une spin-off de <a href=\"https:\/\/www.unibe.ch\/index_fra.html\">l&rsquo;Universit\u00e9 de Berne<\/a> et de l&rsquo;<a href=\"https:\/\/www.insel.ch\/fr\/\">Inselspital<\/a>, s&rsquo;est associ\u00e9e \u00e0 ces institutions pour d\u00e9velopper des tests oculaires avanc\u00e9s destin\u00e9s aux maladies de la r\u00e9tine dans le cadre d&rsquo;une bourse de recherche de CHF 1,1 million. Les maladies de la r\u00e9tine, telles que la d\u00e9g\u00e9n\u00e9rescence maculaire li\u00e9e \u00e0 l&rsquo;\u00e2ge (DMLA) et la r\u00e9tinopathie diab\u00e9tique (RD), devraient conna\u00eetre une croissance spectaculaire et toucher des millions de personnes dans le monde.<\/p>\n\n\n\n<p>Actuellement, les tests fonctionnels de l&rsquo;\u0153il destin\u00e9s aux patients atteints de DMLA et de RD sont limit\u00e9s. Les patients souffrant d&rsquo;une perte de vision centrale, comme ceux atteints de DMLA, ont des difficult\u00e9s \u00e0 effectuer des tests standard tels que le test d&rsquo;acuit\u00e9 visuelle. Bien que la microperim\u00e9trie offre une alternative, elle prend du temps et n\u00e9cessite des ressources importantes, ce qui rend son utilisation peu envisageable \u00e0 grande \u00e9chelle. Il est donc n\u00e9cessaire de trouver des solutions plus efficaces et plus conviviales pour les patients.<\/p>\n\n\n\n<p>S&rsquo;appuyant sur leur expertise dans la combinaison de technologies de pointe &#8211; telles que l&rsquo;intelligence artificielle (IA), la r\u00e9alit\u00e9 virtuelle (VR) et l&rsquo;oculom\u00e9trie &#8211; les partenaires visent \u00e0 d\u00e9velopper des tests oculaires innovants et ind\u00e9pendants de la fixation. Ces nouveaux tests aideront les ophtalmologues \u00e0 mieux \u00e9valuer la fonction visuelle des patients et \u00e0 garantir des diagnostics et des plans de traitement plus pr\u00e9cis, en particulier dans les environnements aux ressources limit\u00e9es.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">R\u00e9pondre aux besoins non satisfaits des patients atteints de maladies r\u00e9tiniennes<\/h4>\n\n\n\n<p>La plateforme VisionOne de PeriVision, qui utilise des casques de RV et de l&rsquo;IA pour optimiser les examens oculaires, a d\u00e9j\u00e0 \u00e9t\u00e9 mise en avant pour son potentiel \u00e0 transformer les diagnostics du glaucome. Aujourd&rsquo;hui, avec ce nouveau partenariat, PeriVision \u00e9tend ses capacit\u00e9s aux maladies de la r\u00e9tine.<\/p>\n\n\n\n<p>Dans le communiqu\u00e9 de presse de l&rsquo;entreprise, le Professeur Raphael Sznitman de l&rsquo;Universit\u00e9 de Berne a soulign\u00e9 la force de la collaboration, citant le partenariat de longue date entre le <a href=\"https:\/\/www.artorg.unibe.ch\/\">centre ARTORG<\/a> et l&rsquo;Inselspital. Le projet vise non seulement \u00e0 am\u00e9liorer les \u00e9valuations cliniques, mais aussi \u00e0 faire progresser le d\u00e9veloppement de solutions de soins oculaires bas\u00e9es dans le cloud.<\/p>\n\n\n\n<p>Cette initiative s&rsquo;appuie sur le succ\u00e8s des travaux ant\u00e9rieurs de PeriVision dans le domaine du glaucome et repr\u00e9sente une avanc\u00e9e significative pour r\u00e9pondre aux besoins non satisfaits des patients atteints de maladies r\u00e9tiniennes.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>PeriVision, en collaboration avec l&rsquo;Inselspital et l&rsquo;Universit\u00e9 de Berne, a re\u00e7u CHF 1,1 million pour d\u00e9velopper de nouveaux tests oculaires pilot\u00e9s par l&rsquo;IA pour les maladies r\u00e9tiniennes telles que la d\u00e9g\u00e9n\u00e9rescence maculaire li\u00e9e \u00e0 l&rsquo;\u00e2ge et la r\u00e9tinopathie diab\u00e9tique.<\/p>\n","protected":false},"author":6,"featured_media":27122,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[845],"tags":[1179,1180,1152,1181,1163],"class_list":["post-27125","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tech","tag-artificial-intelligence-fr-2","tag-digital-health-fr-2","tag-digital-transformation-fr","tag-medical-devices-fr","tag-medtech-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PeriVision l\u00e8ve CHF 1,1M pour la recherche sur les maladies r\u00e9tiniennes<\/title>\n<meta name=\"description\" content=\"PeriVision a re\u00e7u CHF 1,1 million pour d\u00e9velopper de nouveaux tests oculaires pilot\u00e9s par l&#039;IA pour les maladies r\u00e9tiniennes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PeriVision l\u00e8ve CHF 1,1M pour la recherche sur les maladies r\u00e9tiniennes\" \/>\n<meta property=\"og:description\" content=\"PeriVision a re\u00e7u CHF 1,1 million pour d\u00e9velopper de nouveaux tests oculaires pilot\u00e9s par l&#039;IA pour les maladies r\u00e9tiniennes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-01T07:40:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-01T07:43:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/10\/Perivision-1180x811-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"PeriVision obtient CHF 1,1 million pour la recherche sur les maladies de la r\u00e9tine\",\"datePublished\":\"2024-10-01T07:40:32+00:00\",\"dateModified\":\"2024-10-01T07:43:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/\"},\"wordCount\":440,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/10\/Perivision-1180x811-1.jpg\",\"keywords\":[\"Artificial Intelligence\",\"Digital Health\",\"Digital Transformation\",\"Medical Devices\",\"Medtech\"],\"articleSection\":[\"Tech\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/\",\"name\":\"PeriVision l\u00e8ve CHF 1,1M pour la recherche sur les maladies r\u00e9tiniennes\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/10\/Perivision-1180x811-1.jpg\",\"datePublished\":\"2024-10-01T07:40:32+00:00\",\"dateModified\":\"2024-10-01T07:43:23+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"PeriVision a re\u00e7u CHF 1,1 million pour d\u00e9velopper de nouveaux tests oculaires pilot\u00e9s par l'IA pour les maladies r\u00e9tiniennes.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/10\/Perivision-1180x811-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/10\/Perivision-1180x811-1.jpg\",\"width\":1180,\"height\":811,\"caption\":\"Les tests oculaires optimis\u00e9s par l'IA de PeriVision visent \u00e0 am\u00e9liorer les \u00e9valuations fonctionnelles des patients atteints de maladies r\u00e9tiniennes. | \u00a9 PeriVision\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PeriVision obtient CHF 1,1 million pour la recherche sur les maladies de la r\u00e9tine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PeriVision l\u00e8ve CHF 1,1M pour la recherche sur les maladies r\u00e9tiniennes","description":"PeriVision a re\u00e7u CHF 1,1 million pour d\u00e9velopper de nouveaux tests oculaires pilot\u00e9s par l'IA pour les maladies r\u00e9tiniennes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/","og_locale":"fr_FR","og_type":"article","og_title":"PeriVision l\u00e8ve CHF 1,1M pour la recherche sur les maladies r\u00e9tiniennes","og_description":"PeriVision a re\u00e7u CHF 1,1 million pour d\u00e9velopper de nouveaux tests oculaires pilot\u00e9s par l'IA pour les maladies r\u00e9tiniennes.","og_url":"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-10-01T07:40:32+00:00","article_modified_time":"2024-10-01T07:43:23+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/10\/Perivision-1180x811-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"PeriVision obtient CHF 1,1 million pour la recherche sur les maladies de la r\u00e9tine","datePublished":"2024-10-01T07:40:32+00:00","dateModified":"2024-10-01T07:43:23+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/"},"wordCount":440,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/10\/Perivision-1180x811-1.jpg","keywords":["Artificial Intelligence","Digital Health","Digital Transformation","Medical Devices","Medtech"],"articleSection":["Tech"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/","url":"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/","name":"PeriVision l\u00e8ve CHF 1,1M pour la recherche sur les maladies r\u00e9tiniennes","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/10\/Perivision-1180x811-1.jpg","datePublished":"2024-10-01T07:40:32+00:00","dateModified":"2024-10-01T07:43:23+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"PeriVision a re\u00e7u CHF 1,1 million pour d\u00e9velopper de nouveaux tests oculaires pilot\u00e9s par l'IA pour les maladies r\u00e9tiniennes.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/10\/Perivision-1180x811-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/10\/Perivision-1180x811-1.jpg","width":1180,"height":811,"caption":"Les tests oculaires optimis\u00e9s par l'IA de PeriVision visent \u00e0 am\u00e9liorer les \u00e9valuations fonctionnelles des patients atteints de maladies r\u00e9tiniennes. | \u00a9 PeriVision"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/perivision-obtient-chf-11-million-pour-la-recherche-sur-les-maladies-de-la-retine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"PeriVision obtient CHF 1,1 million pour la recherche sur les maladies de la r\u00e9tine"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/27125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=27125"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/27125\/revisions"}],"predecessor-version":[{"id":27127,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/27125\/revisions\/27127"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/27122"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=27125"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=27125"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=27125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}